GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pressure BioSciences Inc (OTCPK:PBIO) » Definitions » ROE %

Pressure BioSciences (Pressure BioSciences) ROE % : 0.00% (As of Sep. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Pressure BioSciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Pressure BioSciences's annualized net income for the quarter that ended in Sep. 2023 was $-22.52 Mil. Pressure BioSciences's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $-26.86 Mil. Therefore, Pressure BioSciences's annualized ROE % for the quarter that ended in Sep. 2023 was N/A%.

The historical rank and industry rank for Pressure BioSciences's ROE % or its related term are showing as below:

PBIO's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.54
* Ranked among companies with meaningful ROE % only.

Pressure BioSciences ROE % Historical Data

The historical data trend for Pressure BioSciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pressure BioSciences ROE % Chart

Pressure BioSciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pressure BioSciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pressure BioSciences's ROE %

For the Medical Devices subindustry, Pressure BioSciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pressure BioSciences's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pressure BioSciences's ROE % distribution charts can be found below:

* The bar in red indicates where Pressure BioSciences's ROE % falls into.



Pressure BioSciences ROE % Calculation

Pressure BioSciences's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-16.077/( (-22.209+-32.686)/ 2 )
=-16.077/-27.4475
=N/A %

Pressure BioSciences's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-22.52/( (-25.115+-28.601)/ 2 )
=-22.52/-26.858
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Pressure BioSciences  (OTCPK:PBIO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-22.52/-26.858
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-22.52 / 1.652)*(1.652 / 1.639)*(1.639 / -26.858)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1363.2 %*1.0079*N/A
=ROA %*Equity Multiplier
=-1373.97 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-22.52/-26.858
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-22.52 / -22.52) * (-22.52 / -5.172) * (-5.172 / 1.652) * (1.652 / 1.639) * (1.639 / -26.858)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 4.3542 * -313.08 % * 1.0079 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Pressure BioSciences ROE % Related Terms

Thank you for viewing the detailed overview of Pressure BioSciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pressure BioSciences (Pressure BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
14 Norfolk Avenue, South Easton, MA, USA, 02375
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
Executives
Daniel Joseph Shea officer: Senior Vice President & CFO 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Bradford Addison Young officer: Chief Commercial Officer 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405
Richard T Schumacher director, officer: Chief Executive Officer 375 WEST STREET, WEST BRIDGEWATER MA 02379
Nathan Lawrence other: VP Sales and Marketing 321 MANLEY STREET, WEST BRIDGEWATER MA 02379
Richard Thomley officer: Chief Financial Officer C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375
Kevin Pollack director 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689
Michael S Urdea director 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507
Alexander V Lazarev officer: VP of REsearch and Development 18 WINCHESTER DRIVE, LEXINGTON MA 02420
Edmund Y Ting officer: Senior VP of Engineering 23642 123RD PLACE SOUTHEAST, KENT WA 48031
Vito J Mangiardi director 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903
Jeffrey N Peterson director 1031 SHORELINE DRIVE, SAN MATEO CA 94404
Mir Conrad F officer: CFO 19 BRIER LANE, CLIFTON NJ 07012
Clayton A Struve 10 percent owner 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604
Css Llc/il other: (a) 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604
R Wayne Fritzsche director 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067

Pressure BioSciences (Pressure BioSciences) Headlines

From GuruFocus